---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-011256"
form_type: "8-K"
ticker: "JAGX"
cik: "0001585608"
company_name: "Jaguar Health, Inc."
filed_at: "2023-02-06T23:59:59+00:00"
generated_at: "2026-06-20T00:04:35.921758+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Jaguar Health and SynWorld Mutually Terminate License Agreement for Canalevia in Dogs in China

## Summary
- Jaguar Health (NASDAQ:JAGX) and SynWorld Technologies terminated the exclusive license agreement for Canalevia (crofelemer) to treat diarrhea in dogs in China, effective January 31, 2023.
- Termination is driven by Jaguar's 2023 strategic focus on human drug development, including Phase 3 OnTarget trial for cancer therapy-related diarrhea.
- SynWorld's General Manager Tao Wang, a long-term shareholder of restricted Jaguar stock, fully supports the mutual termination decision.
- All licenses granted to SynWorld under the agreement were revoked, and rights reverted back to Jaguar.
- Jaguar expects enrollment in the OnTarget trial to complete in Q2 2023; also prioritizing proof-of-concept trial for short bowel syndrome and congenital diarrheal disorders.

## SEC filing metadata
- accession: 0001104659-23-011256
- form_type: 8-K
- ticker: JAGX
- cik: 0001585608
- company_name: Jaguar Health, Inc.
- filed_at: 2023-02-06T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 1.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1585608/000110465923011256/0001104659-23-011256-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1585608/000110465923011256/tm235360d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-011256
- JSON: https://secwatch.observer/filing/0001104659-23-011256.json
- Plain text: https://secwatch.observer/filing/0001104659-23-011256.txt

## Key facts
- Material Agreements
  Jaguar Health, Inc. terminated License Agreement with SynWorld Technologies Corporation, C&E Telecom, LTD, and Tao Wang (effective 2023-01-31).
  - Action: termination
  - Agreement: license
  - Counterparty: SynWorld Technologies Corporation, C&E Telecom, LTD, and Tao Wang
  - Effective: 2023-01-31
  source text: On January 31, 2023, the Company, Licensee, C&E Telecom and Wang entered into a Mutual Termination of License Agreement (the “Termination Agreement”), pursuant to which the parties agreed to mutually terminate the License Agreement, effective as of January 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1585608/000110465923011256/0001104659-23-011256-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.